Key result
Levosimendan administration was not associated with increased postoperative chest drainage volume compared to control in patients undergoing off-pump CABG.
Why the study?
Whether levosimendan is associated with postoperative bleeding and blood transfusion in cardiac surgical patients is controversial.
Does levosimendan increase postoperative chest drainage volume and transfusion requirements in patients undergoing elective off-pump coronary artery bypass grafting?
Cohort (n=292)
No
Does levosimendan increase postoperative chest drainage volume and transfusion requirements in patients undergoing elective off-pump coronary artery bypass grafting?
Levosimendan administration during off-pump CABG does not increase postoperative blood loss or allogeneic blood transfusion requirements.
Answers are grounded in this paper and cite their sources.
Supports levosimendan safety regarding bleeding in off-pump CABG; leaves open need for randomized confirmation.
Background: Levosimendan (LEVO) is a positive inotropic drug which could increase myocardial contractility and reduce the mortality rate in cardiac surgical patients. However, Whether LEVO is associated with postoperative bleeding and blood transfusion in cardiac surgical patients is controversial. Therefore, the current study was designed to investigate the impact of LEVO administration on bleeding and blood transfusion requirement in off-pump coronary artery bypass grafting (OPCAB) patients. Methods: In a retrospective analysis, a total of 292 patients, aged 40–87 years, undergoing elective OPCAB between January 2019 and July 2019, were divided into LEVO group ( n = 151) and Control group ( n = 141). Patients in LEVO group continuously received LEVO at a rate of 0.1–0.2 μg kg −1 min −1 after anesthesia induction until 24 hours after OPCAB or patients in Control group received no LEVO. The primary outcome was postoperative chest drainage volume. The secondary outcomes were reoperation for postoperative bleeding, transfusion requirement of red blood cells (RBCs), fresh frozen plasma (FFP) and platelet concentrate (PC), etc. Comparisons of two groups were performed with the Student’s t-test or Wilcoxon-Mann-Whitney test. Results: There was no significant difference with respect to chest drainage volume ((956.29 ± 555.45) ml vs (1003.19 ± 572.25) ml, p = 0.478) and the incidence of reoperation for postoperative bleeding (1.32% vs 1.42%, p = 0.945) between LEVO group and Control group. The transfusion incidence and volume of allogeneic RBCs, FFP, and PC were comparable between two groups. Conclusions: LEVO administration was neither associated with more postoperative blood loss nor increased allogeneic blood transfusion requirement in OPCAB patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted a cohort in off-pump coronary artery bypass grafting (OPCAB) (n=292). Levosimendan vs. No levosimendan was evaluated on postoperative chest drainage volume (p=0.478). Levosimendan administration was not associated with increased postoperative chest drainage volume compared to control in patients undergoing off-pump CABG.
Synapse has enriched 10 related papers. Consider them for comparative context: